Corange increases stake in IRIS.

CHATSWORTH, Calif.--(BUSINESS WIRE)--Aug. 10, 1995-- International Remote Imaging Systems Inc. (ASE:IRI) (IRIS), Thursday reported that Corange International Ltd., a subsidiary of Corange Ltd., parent company of the Boehringer Mannheim Group, increased its holdings in IRIS through the exercise of a warrant to purchase 248,571 shares of IRIS common stock.

Corange exercised the warrant on July 28, 1995, by payment of $932,141 in cash. As a result, Corange increased its holdings from 220,842 shares of IRIS common stock (or 4.1 percent of the outstanding shares) to 469,413 shares of IRIS common stock (or 8.3 percent of the outstanding shares).

Corange originally obtained the recently exercised warrant in connection with its $1.2 million investment in LDA Systems Inc., a company engaged in a $2.8 million jointly funded program with IRIS to complete development of The White IRIS leukocyte differential analyzer, a new high-speed instrument useful in the classification of white blood cells.

Corange acquired its initial IRIS stock holdings in June of this year in connection with the exchange of its LDA stock in the recent IRIS acquisition of LDA Systems. Corange continues to hold another warrant to purchase 250,000 shares of IRIS common stock for $7.375 per share, an aggregate exercise price of $1,843,750. Corange acquired this warrant in February of this year in connection with its funding of the IRIS and Boehringer Mannheim joint development of a new high-capacity model of The Yellow IRIS automated urinalysis system for use in very large reference and hospital laboratories.

Corange is a Bermuda-based $3.5 billion health care company. With its two operating groups, Boehringer Mannheim and DePuy, Corange is dedicated to improvement of health care worldwide. Corange employs more than 20,000 people and has operating companies in all major countries. Its Diagnostics Division, of which Indianapolis-based Boehringer Mannheim is the main U.S. member, is the second-largest producer of in vitro diagnostic products worldwide. Major products include a diversified line of automated clinical chemistry and immunoassay analyzers, diagnostic reagents, instrumentation and tests for diabetes monitoring, urinalysis and coagulation.

IRIS, a Los Angeles-based company, is the recognized leader in automated microscopic urinalysis. Its main product, The Yellow IRIS urinalysis workstation, is used by hospitals in more than two thirds of U.S. medical schools as well as other leading hospitals nationwide.

IRIS also is the exclusive distributor of CHEMSTRIP/IRIStrip urine chemistry test strips manufactured especially for use in The Yellow IRIS by Boehringer Mannheim Diagnostics. IRIS introduced two new models of The Yellow IRIS and displayed The White IRIS, now awaiting federal regulatory clearance, at the Clinical Laboratory Exposition held in conjunction with the annual meetings of the American Association of Clinical Chemistry and the American Society of Clinical Laboratory Scientists in Anaheim, Calif., last month. IRIS stock trades on the American Stock Exchange under the symbol IRI.

CONTACT: International Remote Imaging Systems Inc., Chatsworth

Dr. Fred H. Deindoerfer, 818/709-1244